Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)

Status unconfirmed

Conditions studied: Esophageal Neoplasms, Esophagectomy, Brain Metastases

In brief

Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ. Brain metastases are rare after esophagectomy for cancer, but they have a serious impact on survival. Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier. There is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes. However, this is not clear yet. A potential explanation could be that chemotherapy disturbs the blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain. The purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer. Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases (comparison between primary surgery and neoadjuvant treatment followed by surgery), time to recurrence and risk factors, number and characteristics of the brain metastases.

Key facts

Study ID

NCT04654975

Run by

Universitaire Ziekenhuizen KU Leuven

People needed

10000

Starts

2020-06-02

Expected to finish

2025-03-31

Last updated by the study team

2024-07-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31 december 2019
• All types of neoadjuvant treatment followed by surgery, primary surgery or salvage surgery.
• Adenocarcinoma or squamous cell carcinoma histology

You may not qualify if…

• other histology type than adenocarcinoma or squamous cell carcinoma
• Hypopharyngeal carcinoma extending to the esophagus (requiring total laryngo-pharyngo-esophagectomy)
• Early esophageal carcinoma (cT IS-1a N0 M0)
• palliative esophagectomy

Where it is running

• Karolinska Institutet — Stockholm, Sweden (enrolling)
• Amsterdam UMC — Amsterdam, Netherlands (enrolling)
• Centre Hospitalier régional Universitaire de Lille — Lille, France
• Saint James Hospital — Dublin, Ireland
• MD Anderson Cancer Center — Houston, Texas, United States
• Zuyderland MC — Heerlen, Netherlands
• Erasmus MC — Rotterdam, Netherlands
• Universitair ziekenhuis Gent — Ghent, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.